Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

643
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
643
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

1.1K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.1K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

320
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
320
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

428
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
428
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

1.7K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
1.7K
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

694
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
694

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Racial and ethnic disparities in clinical outcomes of HER2-positive metastatic breast cancer treated with antibody-drug conjugates.

Journal of the National Cancer Institute·2026
Same author

tRNA-derived fragments elevated in Alzheimer's disease facilitate Tau aggregation.

bioRxiv : the preprint server for biology·2026
Same author

ASO Author Reflections: Neuronal Signature Enrichment Distinguishes a Type of Gastric Cancer with Poor Prognosis.

Annals of surgical oncology·2026
Same author

TP53 mutation is associated with shorter treatment duration with CDK4/6 inhibitors, but not with immune checkpoint inhibitors, in ER-positive/HER2-negative breast cancer: real-world perspective.

Breast cancer research : BCR·2026
Same author

Safety and Efficacy of Direct Oral Anticoagulants Compared to Warfarin in Patients with Venous Thromboembolism and Morbid Obesity.

International journal of hematology-oncology and stem cell research·2026
Same author

BIO26-046: Validating an LLM for Detecting Enrollment Disparities in Breast Cancer Trials.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Related Experiment Video

Updated: Dec 15, 2025

Application of Robot-assisted Pancreaticobiliary Junction Resection in Benign Duodenal Tumors
03:37

Application of Robot-assisted Pancreaticobiliary Junction Resection in Benign Duodenal Tumors

Published on: December 20, 2024

819

Neratinib-Induced Duodenal Ulcer: A Case Report.

Bahar Moftakhar1, Prakash Kharel2, Sujan Niraula3

  • 1Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA.

Breast Cancer : Basic and Clinical Research
|July 9, 2020
PubMed
Summary

A patient taking neratinib for HER2 positive breast cancer developed a duodenal ulcer. This serious gastrointestinal side effect resolved after discontinuing neratinib, highlighting a potential toxicity of the drug.

Keywords:
HER2Neratinibadjuvanttoxicityulcer

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.4K
Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

263

Related Experiment Videos

Last Updated: Dec 15, 2025

Application of Robot-assisted Pancreaticobiliary Junction Resection in Benign Duodenal Tumors
03:37

Application of Robot-assisted Pancreaticobiliary Junction Resection in Benign Duodenal Tumors

Published on: December 20, 2024

819
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.4K
Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

263

Area of Science:

  • Oncology
  • Gastroenterology
  • Pharmacology

Background:

  • Neratinib is a tyrosine kinase inhibitor used in the adjuvant treatment of HER2-positive breast cancer.
  • Gastrointestinal side effects are common with neratinib, but peptic ulcer disease is an under-recognized complication.

Observation:

  • A 37-year-old woman developed a duodenal ulcer during adjuvant neratinib treatment.
  • Abdominal pain correlated with neratinib use, confirmed by esophagogastroduodenoscopy (EGD).

Findings:

  • Neratinib cessation and proton pump inhibitor treatment led to complete duodenal ulcer resolution.
  • The patient's duodenal ulcer resolved within 3 months after stopping neratinib.

Implications:

  • Peptic ulcer disease is a potential serious gastrointestinal toxicity of neratinib.
  • Clinicians should monitor for and recognize gastrointestinal adverse events associated with neratinib.
  • The benefit-risk profile of adjuvant neratinib should be carefully considered in light of potential serious toxicities.